Bharat Biotech Limited Current Affairs, GK & News

India’s first intra-nasal Corona vaccine: GK & Current Affairs Facts

The country’s first intranasal COVID vaccine iNCOVACC by Bharat Biotech has recently received DCGI approval for primary immunization against the infection for people above the age of 18 years. This vaccine has been named ChAd36-SARS-CoV-S COVID-19. Highlights ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) Recombinant Nasal Vaccine for COVID-19 by Bharat Biotech is the first of its ..

Month: 

Category: 

Topics: 

Bharat Biotech’s intranasal vaccine – Update

Bharat Biotech recently sought approval for its intranasal Covid vaccine candidate, BBV154, as two-dose vaccine as well as booster dose. It submitted data from Phase 3 clinical trials of BBV154 to seek approval. Highlights: The heterologous booster infers that, third or subsequent dose of the vaccine is not similar to its primary dose. Usually, primary doses include two ..

Month: 

Category: 

Topics: 

WHO seeks clarifications from Bharat Biotech on Covaxin

According to World Health Organisation (WHO), additional clarifications from manufacturer are required to conduct final Emergency Use Listing (EUL) risk-benefit assessment for using Bharat Biotech’s Covaxin globally. Key Points Technical advisory group are now scheduled to meet on November 3 for final assessment. Bharat Biotech has been submitting data on rolling basis to the WHO. ..

Month: 

Category: 

Topics: 

Covaxin approved for emergency use in 2–18-year-olds

The Subject Expert Committee on Covid-19 has approved the “emergency use” of Bharat Biotech’s Covaxin vaccine for children aged between 2-18 years old. Key Points Phase-2 and Phase-3 trials of the Covaxin vaccine by Hyderabad-based Bharat Biotech on children below the age of 18 years in the months of September. Trial data was submitted to ..

Month: 

Category: 

Topics: 

SII’s Covishield gets emergency-use nod from DGCI

The Subject Expert committee that is advising the Drug Controller General of India (DCGI) recommended restricted Emergency Use Authorisation for COVISHIELD. COVISHIELD vaccine was developed by Serum Institute of India. Who manufactures COVISHIELD? The COVISHIELD the vaccine is developed by the University of Oxford and the British Pharmaceutical major Astra Zeneca. In India, the vaccine ..

Month: 

Category: 

Topics: 

Indigenously Developed ‘COVAXIN’ gets DCGI approval for Human Clinical Trials

The Drug Controller General of India (DCGI) has given approval for Phase I and Phase II human clinical trials for COVID-19 vaccine ‘COVAXIN’. In association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), COVAXIN is developed by Hyderabad based vaccine & bio-therapeutics manufacturer-Bharat Biotech.  At NIV Pune, the ..

Month: 

Category: 

Topics: